secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aligos Therapeutics, Inc. (ALGS)
CIK:        0001799448
Form:       8-K
Filed at:   2024-05-22T23:59:59+00:00
Accession:  0001193125-24-144929
Event type: regulatory
Sentiment:  neutral
Materiality: 0.55
Item codes: 3.01, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Jack Nielsen resigns from board; Aligos out of compliance with Nasdaq Audit Committee rule
--------------------------------------------------------------------------------

- Director Jack Nielsen resigned effective May 21, 2024 for personal reasons; no disagreement with company.
- Audit Committee now has two members; Nasdaq requires three under Rule 5605(c)(2)(A).
- Company notified Nasdaq of non-compliance on May 22, 2024 and plans to cure within 180-day period.
- Aligos intends to appoint a qualified third director to Audit Committee within the cure period.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799448/000119312524144929/0001193125-24-144929-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799448/000119312524144929/d840680d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-144929

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer